Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 4/20 | 0.33 |
| ▸ | ACP1 | P24666 | 2/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7218637 | 0.84 | DDX3X (0.44) | MAPK14 | |
| SCHEMBL7218555 | 0.83 | HDAC3 (0.37) | MAPK14DRD2DRD4DRD3SMN1; SMN2 | |
| SCHEMBL7219299 | 0.79 | MAPK14 (0.37) | MAPK14 | |
| SCHEMBL7213194 | 0.77 | MAPK14 (0.52) | MAPK14 | |
| SCHEMBL7214965 | 0.77 | NPC1 (0.41) | SMN1; SMN2 | |
| SCHEMBL7213379 | 0.74 | NPC1 (0.45) | — | |
| SCHEMBL7215115 | 0.73 | ALDH1A1 (0.39) | — | |
| SCHEMBL7213367 | 0.73 | KMT2A (0.43) | SMN1; SMN2 | |
| SCHEMBL7213350 | 0.73 | KMT2A (0.43) | SMN1; SMN2 | |
| SCHEMBL7218642 | 0.72 | HSD17B10 (0.37) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6624309-B1 | Administering 4-heterocyclicbenzamide derivative | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-23 | — | — | US | disclosed |
| US-20020137968-A1 | Benzoic acid derivatives and related compounds as antiarrhythmic agents | LLOYD JOHN (US) | 2002-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137968-A1 | Benzoic acid derivatives and related compounds as antiarrhythmic agents | SCN1A, SCN1B, NR0B1 | MAPK14 2213/4885ACP1 3298/4885DRD2 1741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.